Lakhani Lab in the news
Associate Professor Pete Simpson, head of the UQCCR Cancer Genomics lab, was invited to speak at the International ILC Virtual Symposium.
This meeting brought together researchers, clinicians and lobular breast cancer advocates, and was supported by the Lobular Breast Cancer Alliance. Invasive Lobular Carcinoma is the second most common type of breast cancer, and it has many unique features. Associate Professor Simpson, Dr Amy McCart Reed and Dr Jamie Kutasovic, together with Professor Sunil Lakhani, have had a longstanding interest in better understanding ILC biology and genetics, and in identifying which ILC tumours are likely to return as a metastasis. Pete gave an overview of our research, and focused on our recent studies on LobSig and also spread of ILC to gynaecological organs.
You can watch the presentation here and learn more about Invasive Lobular Carcinoma here.
Professor Lakhani is lead pathologist on the OlympiA trial, and the first round of results have been presented at the American Society of Oncology Meeting and published in the New England Journal of Medicine.
The results show the benefit of including PARP inhibitor therapy for patients with an inherited mutation in BRCA1/2 and the drug reduced the risk of recurrence, second cancers and death by over 40%. More data will be emerging over the next few years.
- Drug may help more women survive hereditary breast cancer (4 June, 2021)
- OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer (4 June, 2021)
About
Our research focuses on the molecular and cellular basis of breast cancer development, improving the way we predict the risk of relapse, and finding better ways to treat this disease.